APSR2026-719

 
Late-Breaking
Submitted
Oral Presentation
AO28-004
 
 
https://storage.unitedwebnetwork.com/files/1285/1221172-46903-Abstract 2 Presentation_433495.pptx
Format: PPTX Only
 
Format: PDF Only
09. Asthma
8

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Chee-Shee Chai * Universiti Malaysia Sarawak Department of Medicine, Faculty of Medicine and Health Science Kota Samarahan Malaysia
Cessie Valenie Anak Edwin - Universiti Malaysia Sarawak Department of Medicine, Faculty of Medicine and Health Science Kota Samarahan Malaysia
Yen-Shen Wong - Universiti Teknologi MARA Department of Medicine, Faculty of Medicine Sungai Buloh Malaysia
Aisya Natasya Bt Musa - Universiti Teknologi MARA Department of Medicine, Faculty of Medicine Sungai Buloh Malaysia
Am Basheeri B Alias - Universiti Teknologi MARA Department of Medicine, Faculty of Medicine Sungai Buloh Malaysia
Syahrinnaquiah Bt Samsuddin - Universiti Teknologi MARA Department of Medicine, Faculty of Medicine Sungai Buloh Malaysia
Diana-Leh Ching Ng - Universiti Malaysia Sarawak Department of Medicine, Faculty of Medicine and Health Science Kota Samarahan Malaysia
Chong-Kin Liam - Universiti Malaya Department of Medicine, Faculty of Medicine Kuala Lumpur Malaysia
 
 
 
 
 
 
 
Presenting Author Details
Chee-Shee
Chai
cheeshee1981@gmail.com
+60198188265
41-50
Malaysia
Original Research
Th2 asthma demonstrates a trend towards poorer control despite higher treatment intensity: a cohort study
Maximum 25 words
Abstract Content
T helper type 2 (Th2) asthma is characterised by eosinophilic airway inflammation mediated by Th2 lymphocytes and innate lymphoid cells, involving cytokines IL-4, IL-5, and IL-13. It is hypothesised to be more responsive to inhaled corticosteroid (ICS)-based therapy. This study aimed to compare asthma control and exacerbation patterns between Th2 and non–Th2 asthma.
A cohort study was conducted from March 2023 to February 2026 at the respiratory specialist clinics of Universiti Malaysia Sarawak and Hospital Al-Sultan Abdullah, Malaysia. Adults aged ≥18 years with asthma on ICS therapy were enrolled and followed up longitudinally. Asthma control assessed using the asthma control test (ACT), was categorised as well controlled, partially controlled, or poorly controlled (ACT score ≥20, 15-19, or <15, respectively). Exacerbations were classified as severe (requiring hospital admission), moderate (requiring emergency department attendance or unscheduled clinic visit), or mild (self-managed with reliever therapy).
Of 148 patients, 73.0% were of Th2 phenotype and 27.0% non-Th2 phenotype. Mean duration of follow-up was similar (26.5 ± 10.4 vs 25.7 ± 15.2 months, p=0.709). A higher proportion of Th2 patients were on Step 5 treatment (14.8% vs 5.0%; p=0.105). Th2 patients showed a trend towards poorer control, with lower nadir ACT scores (17.2 ± 4.8 vs 17.8 ± 4.6) and a higher proportion with poor control (28.3% vs 14.3%), with p-values ranging 0.462 – 0.489. Moderate-to-severe exacerbation rates were similar (76.9% vs 75.0%, p=0.814). However, a higher proportion of non–Th2 patients had severe exacerbations (20.0% vs 13.9%) (p=0.362).
Patients with Th2 asthma showed a trend towards poorer control despite greater use of Step 5 therapy, but with fewer severe exacerbations. These findings could have been influenced by treatment effects and smaller non-Th2 sample size. Further adequately powered studies are needed to clarify phenotype-related outcomes.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Bronchial asthma, asthma control test, exacerbation
maximum 3 keywords and no abbreviations, separated by commas
This study was supported by the Vice-Chancellor High Impact Research Grant Scheme of Universiti Malaysia Sarawak (UNI/F05/VC-HIRG/85478/P01-02/2022). The authors declare no conflicts of interest.
315